Surmodics Q3 EPS $0.52 May Not Be Comparable To $(0.46) Estimate, Sales $52.48M Beat $26.70M Estimate
Portfolio Pulse from Benzinga Newsdesk
Surmodics reported Q3 earnings of $0.52 per share, beating the analyst consensus estimate of $(0.46) by 213.04%. This is a 252.94% increase over losses of $(0.34) per share from the same period last year. The company also reported quarterly sales of $52.48 million, beating the analyst consensus estimate of $26.70 million by 96.57%. This is a 111.17% increase over sales of $24.85 million the same period last year.
August 04, 2023 | 10:59 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Surmodics reported strong Q3 earnings and sales, significantly beating estimates and showing a substantial increase over the same period last year.
Surmodics reported Q3 earnings and sales that significantly beat estimates. This strong performance, which includes a 252.94% YoY increase in earnings and a 111.17% YoY increase in sales, is likely to have a positive impact on the company's stock in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100